P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

ABSTRACT:

SUBMITTER: Silvennoinen R 

PROVIDER: S-EPMC10430912 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature